NCT07465224: An ongoing trial by Alnylam Pharmaceuticals
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07465224 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Study Investigating the Effect of ALN-4324 on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 15, 2026 |
| Completion date | May 28, 2027 |
| Required reporting date | May 27, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 11, 2026 |
| Days late | None |